



Certificate of Analysis

Human Interferon Alpha G (Alpha 5)

Catalog No: 11135-1

Lot No: 6869

Size: $\geq 1 \times 10^5$ units/vial

Description: Recombinant Human Interferon Alpha G (Alpha 5) (Hu-IFN- α G; Hu-IFN- α 5)

Volume: 0.100 ml

Activity: 4.33×10^6 units/ml (MDBK/VSV)

Specific Activity: 2.70×10^8 units/mg (MDBK/VSV)

Buffer: Phosphate buffered saline (PBS) containing 0.1% bovine serum albumin (BSA)

Endotoxin: < 1 EU/ μ g

Molecular Weight: 19.5 kDa

Purity: $\geq 95\%$

Purification Method: Purified from *E. coli* by a combination of ion exchange, hydrophobic interaction and size exclusion chromatography

Source: cDNA obtained from human leukocyte mRNA expressed in *E. coli*

Human Gene: IFNA5

Synonyms: Hu-IFN- α 25

Accession #: X02956

Assay Used to Measure Bioactivity: Interferon was titrated with the use of the cytopathic effect inhibition assay as listed

Bovine (MDBK/VSV) – performed as described [Rubinstein, *et al.* (1981) *J. Virol.* 37(2):755]. The EC₅₀ for interferon in this assay is ~ 5 U/ml. Lot Activity was derived from multiple determinations in the above assay.

Human (A549/EMCV) – performed as described [Budd, *et al.* (1985) *Canc. Chem. Pharm.* 12:39]. The EC₅₀ for interferon in this assay is ~ 1 U/ml. **Activity:** 6.18×10^6 units/ml **Specific Activity:** 3.86×10^8 units/mg

The units are determined by use of a Human IFN Alpha A (Hu-IFN- α A [2a]) laboratory standard calibrated to the international reference standard for Human Interferon Alpha A (Hu-IFN- α A [2a]) provided by the National Institutes of Health [Meager, *et al.* (2001). *J. Immunol. Meth.* 257(1-2):17-33]. Please note that IFN assays vary between labs and assay systems [Meager, *et al.* (2001) *J. Immunol. Meth.* 257:17. Meager and Das (2005) *J. Immunol. Meth.* 306:1].

Shipping Conditions: Dry Ice

Physical State of Product During Shipping: Frozen

Storage Conditions/Comments: After receipt, the product may be stored at -20°C for short-term use (≤ 6 months). For long-term storage, we recommend storing the product at -70°C or below for retention of full activity. When thawing, the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum. Refreezing should be done on dry ice or in a dry ice/alcohol bath. Further dilution of the product should be in buffers containing protein such as 0.1% bovine serum albumin (BSA) or tissue culture media with serum. Dilution of material below 2×10^5 units/ml for freezing is not recommended. One freeze-thaw cycle is equivalent to thawing an aliquot prepared from the material received. [The activity measured after one freeze-thaw cycle is 2.88×10^6 units/ml (MDBK/VSV)]. For more information on protein handling, visit our Resource Library at www.pbl assaysci.com.

Authorization

Released by: _____

Date: March 20, 2018

Sold under license from Pestka Biomedical Laboratories, Inc. d/b/a PBL Assay Science. For research use only. Not for diagnostic or clinical use in, or administration to, humans. Not for resale in original or any modified form, including inclusion in a kit, for any purpose. Not for use in the preparation of any commercial product.

Rev. 02